Earnings and Revenue Growth Expectations of Aspen Pharmacare Holdings Limited Worry Experts
Aspen Pharmacare Holdings Limited’s stock price closed at 17,666.00 on this Friday, March 7th, with a daily change of 128.00 or 0.73 percent from the previous trading session. Over the past four weeks, the company’s stock has gained 4.58 percent, and over the last 12 months, it has fallen by 13.28 percent. According to Trading Economics’ global macro models and analysts’ expectations, Aspen Pharmacare is forecasted to be priced at 16,218.96 by the end of this quarter and at 15,890.33 in one year.
Time: 1741390996
Company: Aspen Pharmacare
Stock Price in Rands (ZAR): 17,666.00
Daily Change: 128.00 (0.73%)
Monthly Change: 4.58%
Yearly Change: -13.28%
Quarterly Forecast: 16,218.96
Trends and Insights
Aspen Pharmacare’s Shares Surge, Prices Expected to Continue Rising
Aspen Pharmacare’s stock closed at 17,666.00 on Friday, March 7th, marking a 0.73% increase from the previous trading session. The company’s performance over the past four weeks has also been impressive, with a 4.58% gain. However, when looking at the long-term picture, Aspen Pharmacare’s price has taken a hit, falling by 13.28% over the past 12 months.
Despite this, analysts are forecasting a brighter future for the company, with predictions that it will be priced at 16,218.96 by the end of the quarter and 15,890.33 by next year, according to Trading Economics’ global macro models and analyst expectations. These projections suggest that investors may want to keep an eye on Aspen Pharmacare, as its stock could continue to rise in the coming months.
Company Profile
Aspen Pharmacare Holdings Limited is a global leader in the pharmaceutical industry, with a strong presence in over 50 countries worldwide. The company is headquartered in South Africa and is renowned for its complex manufacturing capabilities in active pharmaceutical ingredients (APIs) and finished dose form. With a diverse range of product offerings, Aspen Pharmacare is focused on providing a broad portfolio of post-patent, branded medicines and domestic brands to both hospital and consumer markets. The company operates through two primary business segments: Manufacturing and Commercial Pharmaceuticals.
Its Manufacturing segment caters to third-party customers, offering a wide range of APIs and finished dose form products. The Commercial Pharmaceuticals segment is divided into two categories, Regional Brands and Sterile Focus Brands, which include Anaesthetics and Thrombosis products. Aspen Pharmacare operates around 23 manufacturing facilities across six continents, producing a diverse array of products such as orals, liquids, steriles, biologicals, and APIs. With its extensive global reach and expertise, Aspen Pharmacare has established itself as a trusted partner in the pharmaceutical industry.
